Poseida Therapeutics, Inc. Common Stock
PSTX
PSTX was delisted on the 7th of January, 2025.
71 hedge funds and large institutions have $279M invested in Poseida Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 15 increasing their positions, 21 reducing their positions, and 6 closing their positions.
150% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 6
15% more funds holding
Funds holding: 62 → 71 (+9)
1% more capital invested
Capital invested by funds: $276M → $279M (+$3.07M)
29% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 21
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
+$1.81M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$718K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$713K |
| 4 |
State Street
Boston,
Massachusetts
|
+$558K |
| 5 |
PG
Pendal Group
Sydney,
Australia
|
+$435K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$6.43M |
| 2 |
BlackRock
New York
|
-$2.55M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.44M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$1.04M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.03M |
PSTX Hedge Fund Activity: Q2 2021 in Review
71 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Poseida Therapeutics, Inc. Common Stock (PSTX) for Q2 2021, worth a combined $279M — up 1.1% from $276M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new PSTX positions and 6 closed out — a net gain of 9 holders — while 15 added to existing stakes and 21 trimmed.
The largest buyer was J. Goldman & Co, opening a new position worth an estimated $1.81M. The largest seller was Millennium Management, cutting an estimated $6.43M.
- 71 institutional investors held Poseida Therapeutics, Inc. Common Stock (PSTX) as of Q2 2021, up from 62 in Q1 2021.
- Funds reported $279M of Poseida Therapeutics, Inc. Common Stock stock for Q2 2021, up 1.1% quarter-over-quarter.
- 15 funds opened new Poseida Therapeutics, Inc. Common Stock positions in Q2 2021 and 6 closed out, a net change of +9 holders.
- The largest Poseida Therapeutics, Inc. Common Stock buyer in Q2 2021 was J. Goldman & Co, an estimated $1.81M added.
- The largest Poseida Therapeutics, Inc. Common Stock seller in Q2 2021 was Millennium Management, an estimated $6.43M sold.
Based on aggregated 13F filings for Q2 2021.